Kunj Sachdeva1, Anil Kumar2,3, Sujata Mohanty1. 1. Stem Cell Facility (DBT-Centre of Excellence for Stem Cell Research), All India Institute of Medical Sciences, New Delhi, India. 2. Amity Institute of Biotechnology, Amity University Haryana, Amity Education Valley, Gurugram, India. 3. School of Engineering and Sciences, GD Goenka University, Gurugram, Haryana, India.
Abstract
OBJECTIVE: The objective of this review article is to outline the pathology, virology and mechanism of severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) and to study the regenerative role of mesenchymal stem cells (MSCs) to tackle the lung damage caused by SARS-CoV-2. BACKGROUND: The MSCs possess trophic potentialities which enable them to find out the sites of injury or inflammation and because of their pleiotropic and pericytic nature, these cells are capable of differentiating into different cell types. The MSCs can be derived from a variety of tissue sources be it adult or embryonic origin. The one major characteristic of MSCs is that they are immunologically naïve in terms of expression of MHC Class II. This very low or no expression of MHC class II makes them useful in clinical settings where they can be used in allogenic transplant cases. This allogenic transplant possibilities of these MSCs makes them one of the most researched stem cells and investigated for cell-based therapies. Though these MSCs are in clinical settings for long the one even more important characteristic which makes them even more in demand is their immunomodulatory properties which have been used in various cases to mitigate the effect of overstimulation of the immune system. In recent times after the pandemic of the novel corona virus disease 2019 (nCOVID-19) generated by SARS-CoV-2, the effect of various MSCs isolated from various tissue sources are being utilized to curb the overstimulation of immune response, so that the immune system can be brought under some regulation to ultimately reduce the effect of inflammation. METHODS: In this review article, we have reviewed the existing literature, data and ongoing clinical trials by using keywords like novel coronavirus, COVID-19, SARS-CoV-2, MERS-CoV, acute respiratory distress syndrome, mesenchymal stem cells, immunomodulation properties of stem cells, regenerative properties of stem cells, cell therapy, clinical trials of stem cells, clinical trials of COVID-19 and stem cells till 20th August 2020 using database named PubMed, NCBI, Google Scholar, Scopus, Research Gate and Clinicaltrials.gov. CONCLUSIONS: Thus, concluding the therapeutic potential of MSCs in managing and treating COVID-19. 2021 Stem Cell Investigation. All rights reserved.
OBJECTIVE: The objective of this review article is to outline the pathology, virology and mechanism of severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) and to study the regenerative role of mesenchymal stem cells (MSCs) to tackle the lung damage caused by SARS-CoV-2. BACKGROUND: The MSCs possess trophic potentialities which enable them to find out the sites of injury or inflammation and because of their pleiotropic and pericytic nature, these cells are capable of differentiating into different cell types. The MSCs can be derived from a variety of tissue sources be it adult or embryonic origin. The one major characteristic of MSCs is that they are immunologically naïve in terms of expression of MHC Class II. This very low or no expression of MHC class II makes them useful in clinical settings where they can be used in allogenic transplant cases. This allogenic transplant possibilities of these MSCs makes them one of the most researched stem cells and investigated for cell-based therapies. Though these MSCs are in clinical settings for long the one even more important characteristic which makes them even more in demand is their immunomodulatory properties which have been used in various cases to mitigate the effect of overstimulation of the immune system. In recent times after the pandemic of the novel corona virus disease 2019 (nCOVID-19) generated by SARS-CoV-2, the effect of various MSCs isolated from various tissue sources are being utilized to curb the overstimulation of immune response, so that the immune system can be brought under some regulation to ultimately reduce the effect of inflammation. METHODS: In this review article, we have reviewed the existing literature, data and ongoing clinical trials by using keywords like novel coronavirus, COVID-19, SARS-CoV-2, MERS-CoV, acute respiratory distress syndrome, mesenchymal stem cells, immunomodulation properties of stem cells, regenerative properties of stem cells, cell therapy, clinical trials of stem cells, clinical trials of COVID-19 and stem cells till 20th August 2020 using database named PubMed, NCBI, Google Scholar, Scopus, Research Gate and Clinicaltrials.gov. CONCLUSIONS: Thus, concluding the therapeutic potential of MSCs in managing and treating COVID-19. 2021 Stem Cell Investigation. All rights reserved.
Authors: Ulrich Nöth; Anna M Osyczka; Richard Tuli; Noreen J Hickok; Keith G Danielson; Rocky S Tuan Journal: J Orthop Res Date: 2002-09 Impact factor: 3.494
Authors: Ellen Gorman; Manu Shankar-Hari; Phil Hopkins; William S Tunnicliffe; Gavin D Perkins; Jonathan Silversides; Peter McGuigan; Colette Jackson; Roisin Boyle; Jamie McFerran; Cliona McDowell; Christina Campbell; Margaret McFarland; Jon Smythe; Jacqui Thompson; Barry Williams; Gerard Curley; John G Laffey; Mike Clarke; Cecilia O'Kane; Daniel F McAuley Journal: Trials Date: 2020-06-03 Impact factor: 2.279
Authors: Ioannis Alexandros Charitos; Andrea Ballini; Roberto Lovero; Francesca Castellaneta; Marica Colella; Salvatore Scacco; Stefania Cantore; Roberto Arrigoni; Filiberto Mastrangelo; Mario Dioguardi Journal: Int J Environ Res Public Health Date: 2022-08-28 Impact factor: 4.614